- Home
- PDM vs XERS Comparison
PDM vs XERS Comparison
Compare PDM & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDM | XERS |
|---|---|---|
| Founded | 1997 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.8M | 936.3M |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PDM | XERS |
|---|---|---|
| Price | $6.56 | $5.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $9.00 | ★ $10.83 |
| AVG Volume (30 Days) | 805.0K | ★ 1.9M |
| Earning Date | 04-27-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $564,994,000.00 | $49,590,000.00 |
| Revenue This Year | $2.60 | $34.22 |
| Revenue Next Year | $1.57 | $22.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $5.46 | $3.81 |
| 52 Week High | $9.19 | $10.08 |
Technical Indicators
Market Signals| Indicator | PDM | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 32.39 |
| Support Level | N/A | $4.87 |
| Resistance Level | $7.83 | $5.49 |
| Average True Range (ATR) | 0.21 | 0.23 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 10.94 | 3.52 |
Price Performance
Historical ComparisonAbout PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.